Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
Add more filters










Database
Language
Publication year range
1.
Crit Rev Oncol Hematol ; 193: 104217, 2024 Jan.
Article in English | MEDLINE | ID: mdl-38040072

ABSTRACT

Molecular biomarker testing is increasingly becoming standard of care for advanced non-small cell lung cancer (NSCLC). Tissue and liquid biopsy-based next-generation sequencing (NGS) is now highly recommended and has become an integral part of the routine management of advanced NSCLC patients. This highly sensitive approach can simultaneously and efficiently detect multiple biomarkers even in scant samples. However full optimization of NGS in clinical practice requires accurate reporting and interpretation of NGS findings. Indeed, as the number of NSCLC biomarkers continues to grow, clinical reporting of NGS data is becoming increasingly complex. In this scenario, achieving standardization, simplification, and improved readability of NGS reports is key to ensuring timely and appropriate treatment decisions. In an effort to address the complexity and lengthy reporting of NGS mutation results, an Italian group of 14 healthcare professionals involved in NSCLC management convened in 2023 to address the content, structure, and ease-of-use of NGS reporting practices and proposed a standard report template for clinical use This article presents the key discussion points addressed by the Italian working group and describes the essential elements of the report template.


Subject(s)
Carcinoma, Non-Small-Cell Lung , Lung Neoplasms , Humans , Carcinoma, Non-Small-Cell Lung/diagnosis , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/therapy , Lung Neoplasms/diagnosis , Lung Neoplasms/genetics , Lung Neoplasms/therapy , Biomarkers, Tumor/genetics , High-Throughput Nucleotide Sequencing/methods , Mutation , Italy
2.
J Thorac Dis ; 12(7): 3877-3882, 2020 Jul.
Article in English | MEDLINE | ID: mdl-32802469

ABSTRACT

Being lung cancer the main cause of cancer-related mortality worldwide, mainly dependent on tobacco consumption, fighting the tobacco epidemic and concretely acting in terms of prevention represents a current urgent need. Indeed, it has become clear that the significant reduction in tobacco consumption would result in the prevention of a large fraction of lung cancer cases and other smoking-related diseases. Women Against Lung Cancer in Europe (WALCE) is a non-profit European organisation with more than 10 years of experience, whose mission is promoting communication strategies and awareness initiatives, customized on recipients age, to aware public opinion and decision makers on damages of smoking on health and spreading accurate and updated information in order to support people affected by lung cancer and their caregivers. In this review we will provide a summary of WALCE commitment and experience in the field of smoking cessation and lung cancer prevention.

3.
Clin Respir J ; 12(3): 1150-1159, 2018 Mar.
Article in English | MEDLINE | ID: mdl-28466511

ABSTRACT

INTRODUCTION: Smoking is the major risk factor for cancer and several respiratory diseases. Quitting smoking at any point of life may increase the effectiveness of treatments and improve prognosis of patients with any pulmonary disease, including lung cancer. However, few institutions in Europe offer to patients adequate counseling for smoking cessation. OBJECTIVES: Aim of this study was to investigate the level of counseling for smoking cessation offered by healthcare professionals to patients and their appreciation towards the intervention itself. METHODS: Between January 2013 and February 2016, 490 patients, diagnosed with a respiratory diseases, were prospectively evaluated with an anonymous survey developed by WALCE (Women Against Lung Cancer in Europe). RESULTS: The majority of patients enrolled (76%) declared to have stopped smoking after the diagnosis of a respiratory disease, 17% to smoke less, 7% to continue smoking. Patients who reported to have never received any counseling for smoking cessation were 38%. Almost 73% of the other patients reported a positive judgment about the quality of healthcare's intervention. Despite these favorable considerations, 83% of patients have disclosed they simply quit smoking overnight without help, 5% have used electronic cigarettes, 5% nicotine replacement treatments, 4% dedicated books, 3% have attended a referral clinic. CONCLUSIONS: Considering all the smoking-related side effects, greater efforts should be made in order to better support patients in smoking cessation. Smoking should be considered as a real physical disorder and similar surveys should be encouraged with the aim to fight the 'stigma' of smoking that still exists among patients.


Subject(s)
Counseling/methods , Respiratory Tract Diseases/epidemiology , Smoking Prevention/methods , Smoking/adverse effects , Surveys and Questionnaires , Adolescent , Adult , Aged , Female , Follow-Up Studies , Humans , Italy/epidemiology , Male , Middle Aged , Morbidity/trends , Prognosis , Respiratory Tract Diseases/diagnosis , Retrospective Studies , Risk Factors , Smoking/epidemiology , Smoking Cessation/methods , Young Adult
4.
Biomed Hub ; 2(Suppl 1): 22-25, 2017.
Article in English | MEDLINE | ID: mdl-31988926

ABSTRACT

We are, understandably, forever hearing about the high cost of bringing innovative new drugs and treatments to the healthcare market, especially medicines for smaller subgroups, and the fact that member state health systems often baulk at the prices. This article will argue that such a bypassing and blocking of innovative medicines and treatments is not only counterproductive when it comes to the health of Europe's patients, but actually fails to take into account the economic arguments. The article seeks to show that the long-term benefit to patients and the economy (health means wealth) will outweigh initial costs down the line. Couple this with a smarter use of information technologies and other resources and it will be possible to get much closer to building sustainable healthcare systems in a Europe struggling under the burden of an ageing population.

6.
Lung Cancer Manag ; 6(3): 93-107, 2017 Dec.
Article in English | MEDLINE | ID: mdl-30643575

ABSTRACT

Lung cancer is the leading cause of cancer-related deaths in worldwide, and NSCLC represents around 85% of all lung cancers. Squamous cell lung cancer (SqCLC) is the second most common subtype and it is challenging to treat. New options have been discovered but progresses are still limited for the lack of 'druggable' mutations. Specific resources for SqCLC are limited and this condition affects treatment and outcomes. This paper describes available and emerging therapeutic options and resources that may help patients to face their disease. We have also performed a monocentric survey collecting information about smoking habit and sense of guilty and analyzed the possibility for patients to find helpful sources for their disease. The results suggest that more materials focused on SqCLC are still needed.

SELECTION OF CITATIONS
SEARCH DETAIL
...